

Resource Summary Report

Generated by [nidm-terms](#) on Aug 17, 2026

CD4 Antibody, anti-mouse, VioGreen™, REAfinity™

RRID:AB_2734087

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-118-693, RRID:AB_2734087

Antibody Information

URL: http://antibodyregistry.org/AB_2734087

Proper Citation: Miltenyi Biotec Cat# 130-118-693, RRID:AB_2734087

Target Antigen: CD4

Host Organism: human

Clonality: monoclonal

Comments: Info: This product is a higher concentration for optimized use in multicolor flow cytometry panels. It replaces product cat # 130-109-492. (RRID:AB_2657963).
Info: This product is a higher concentration for optimized use in multicolor flow cytometry panels. It replaces product cat # 130-109-413. (RRID:AB_2657964).

Antibody Name: CD4 Antibody, anti-mouse, VioGreen™, REAfinity™

Description: This monoclonal targets CD4

Target Organism: mouse

Clone ID: clone REA604

Antibody ID: AB_2734087

Vendor: Miltenyi Biotec

Catalog Number: 130-118-693

Record Creation Time: 20250820T005128+0000

Record Last Update: 20250820T092332+0000

Ratings and Alerts

No rating or validation information has been found for CD4 Antibody, anti-mouse, VioGreen™, REAfinity™.

No alerts have been found for CD4 Antibody, anti-mouse, VioGreen™, REAfinity™.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Fumet JD, et al. (2026) Tumor-Associated Macrophages Produce PGE2 to Promote CD8+ T-cell Exhaustion and Drive Resistance to PD-L1 Blockade in Microsatellite-Stable Colorectal Cancer. Cancer research, 86(3), 785.

Georgievski A, et al. (2026) Valrubicin-loaded immunoliposomes targeting antigens on immunosuppressive cells to circumvent resistance to cancer immunotherapy. Cell reports. Medicine, 7(3), 102632.

Gauthier J, et al. (2026) B cell-intrinsic IL-2 signaling regulates inflammation by promoting IL-10 expression in CD25+ age-associated B cells. Immunity, 59(2), 354.

Bülow S, et al. (2024) Bactericidal/permeability-increasing protein instructs dendritic cells to elicit Th22 cell response. Cell reports, 43(3), 113929.

Limagne E, et al. (2022) MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells. Cancer cell, 40(2), 136.